Reevaluation of a case of type 1 diabetes mellitus diagnosed before 6 months of age

Nature Reviews Endocrinology

Volumn 6, Issue 6, 2010, Pages 347-351

  Jones, Angus G ^a   Hattersley, Andrew T ^a  

^a PENINSULA MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; C PEPTIDE; GLIBENCLAMIDE; GLUCOSE; GLUTAMATE DECARBOXYLASE ANTIBODY; HEMOGLOBIN A1C; INSULIN; KETONE; PROTEIN SUBUNIT; SULFONYLUREA;

ADOLESCENT; ANAMNESIS; ARTICLE; BLOOD GLUCOSE MONITORING; CASE REPORT; CLINICAL FEATURE; DEVELOPMENTAL DISORDER; DIARRHEA; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG SUBSTITUTION; ELECTROENCEPHALOGRAPHY; EPILEPSY; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GLYCEMIC CONTROL; HETEROZYGOSITY; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; KETOACIDOSIS; LEARNING DISORDER; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ADOLESCENT; AMINO ACID SUBSTITUTION; DEVELOPMENTAL DISABILITIES; DIABETES MELLITUS, TYPE 1; DOSE-RESPONSE RELATIONSHIP, DRUG; EPILEPSY; FEMALE; GLYBURIDE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INFANT; METHIONINE; MUTATION; POTASSIUM CHANNELS, INWARDLY RECTIFYING; SYNDROME; VALINE;

EID: 77952954628     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2010.42     Document Type: Article

References (17)

1. Pihoker, C., Gilliam, L. K., Hampe, C. S. & Lernmark, A. Autoantibodies in diabetes. Diabetes 54 (Suppl. 2) S52-S61 (2005).
2. van Deutekom, A. W., Heine, R. J. & Simsek, S. The islet autoantibody titers: their clinical relevance in latent autoimmune diabetes in adults (LADA) and the classification of diabetes mellitus. Diabet. Med. Feb. 25, 117-125 (2008).
3. Edghill, E. L. et al. HLA genotyping supports a nonautoimmune etiology in patients diagnosed with diabetes under the age of 6 months. Diabetes 55, 1895-1898 (2006).
4. Iafusco, D. et al. Permanent diabetes mellitus in the first year of life. Diabetologia 45, 798-804 (2002).
5. Stoy, J. et al. Diagnosis and treatment of neonatal diabetes: a United States experience. Pediatr. Diabetes 9, 450-459 (2008).
6. Edghill, E. L. et al. Insulin mutation screening in 1, 044 patients with diabetes: mutations in the INS gene are a common cause of neonatal diabetes but a rare cause of diabetes diagnosed in childhood or adulthood. Diabetes 57, 1034-1042 (2008).
7. Flanagan, S. E., Edghill, E. L., Gloyn, A. L., Ellard, S. & Hattersley A. T. Mutations in KCNJ11, which encodes Kir6. 2, are a common cause of diabetes diagnosed in the first 6 months of life, with the phenotype determined by genotype. Diabetologia 49, 1190-1197 (2006).
8. Temple, I. K. et al. Transient neonatal diabetes: widening the understanding of the etiopathogenesis of diabetes. Diabetes 49, 1359-1366 (2000).
9. Flanagan, S. E. et al. Mutations in ATP-sensitive K+ channel genes cause transient neonatal diabetes and permanent diabetes in childhood or adulthood. Diabetes 56, 1930-1937 (2007).
10. Gloyn, A. L. et al. Activating mutations in the gene encoding the ATP-sensitive potassiumchannel subunit Kir6. 2 and permanent neonatal diabetes. N. Engl. J. Med. 350, 1838-1849 (2004).
11. Hattersley, A. T. & Ashcroft, F. M. Activating mutations in Kir6. 2 and neonatal diabetes: new clinical syndromes, new scientific insights, and new therapy. Diabetes 54, 2503-2513 (2005).
12. Pearson, E. R. et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6. 2 mutations. N. Engl. J. Med. 355, 467-477 (2006).
13. Rafiq, M. et al. Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations. Diabetes Care 31, 204-209 (2008).
14. Babenko, A. P. et al. Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N. Engl. J. Med. 355, 456-466 (2006).
15. Slingerland, A. S. et al. Sulfonylurea therapy improves cognition in a patient with the V59M KCNJ11 mutation. Diabet. Med. 25, 277-281 (2008).
16. Slingerland, A. S., Nuboer R., Hadders-Algra, M., Hattersley, A. T. & Bruining, G. J. Improved motor development and good long-term glycemic control with sulfonylurea treatment in a patient with the syndrome of intermediate developmental delay, early-onset generalised epilepsy and neonatal diabetes associated with the V59M mutation in the KCNJ11 gene. Diabetologia 49, 2559-2563 (2006).
17. Mlynarski, W. et al. Sulfonylurea improves CNS function in a case of intermediate DEND syndrome caused by a mutation in KCNJ11. Nat. Clin. Pract. Neurol. 3, 640-645 (2007).